Study Title:Compassionate use of Smart home technology: Understanding the desires of informal carers of persons with dementia living in the community
Study Description:The objective of the research project is to promote the compassionate use of smart home technology by understanding what informal carers of persons with dementia living in the community desire with respect to the selection and use of smart home technology. You’ll be asked to partake in a 40 minute interview exploring current experiences caring for your loved one with dementia and ways in which smart home technology could support your ability to provide care.
Eligibility Criteria:- Informal caretaker of a person with dementia
- May live with the person with dementia, or apart
- Able to communicate during an interview either in-person, on the phone or by videoconferencing
Recruitment Close Date:December 23, 2022
Principal Investigator:Lisa Sheehy, PhD
Contact:Caroline Lasia, Research Assistant
Phone: 613-562-6262 ext. 1270
Email:
clasia@bruyere.org REB#:M16-022-027. This study has been approved by the Bruyère Research Ethics Board.
Study Title:
The Role of Our Gut Bacteria in Alzheimer’s Disease
Study Description:There are over 1000 types of bacteria that live in our gut and help us to process foods and help in nutrient and vitamin uptake. Recently, it was discovered that there are disturbances in the gut bacteria of people who have Alzheimer’s disease. Laboratory tests can determine the number and type of gut bacteria from a stool sample.
This information will help to compare the gut bacteria in people living with memory problems such as Alzheimer’s disease to those who do not have memory problems. This research may help develop therapies to improve unhealthy gut bacteria which may be able to improve the symptoms of Alzheimer’s disease and/or slow its progression.
Eligibility Criteria:
- Individuals age 50+ who:
- Are not experiencing any memory problems; OR
- Have Alzheimer’s disease
- Are prepared to provide 2 stool samples, 3-6 months apart, and fill out questionnaires
Recruitment Close Date:
Principal Investigator:
Dr. Andrew Frank
Contact:
Clinical Trials Research Unit: 613-562-6328 or
ctu@bruyere.org
REB#:
M16-19-039. This study has been approved by the Bruyère Research Ethics Board.
Study Title:
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of AL002 in Participant with Early Alzheimer’s Disease
Study Description:This study’s purpose is to determine if the investigational drug AL002 is effective and safe in treating individuals who have mild Alzheimer’s disease when compared to placebo (non-active).
The investigational drug (AL002) aims to stimulate the body’s immune response to remove protein waste that is thought to contribute to Alzheimer’s disease. Participants in the study will receive the investigational product (or placebo) intravenously once every 4 weeks.
Eligibility Criteria:
- Aged between the years 50 to 85 years of age
- Have a diagnosis of Mild Cognitive Impairment, Mild Dementia or Mild Alzheimer’s
- Has someone who can be their study partner
- Note: This list is not exhaustive. Please contact the Clinical Trials Research Unit to find out more.
Recruitment Close Date:
December 31, 2022
Principal Investigator:
Dr. Andrew Frank
Contact:
Clinical Trials Research Unit: 613-562-6328 or
ctu@bruyere.org
REB#:
M16-21-015. This study has been approved by the Bruyère Research Ethics Board.
Study Title:A randomized Phase IIa, multi-center, double-blind, placebo-controlled study to assess the safety, feasibility, tolerability, and efficacy of a new buccal film of montelukast in patients with mild to moderate Alzheimer’s Disease
Study Description:Alzheimer’s disease is the most common cause of dementia and it continues to grow worldwide as the population ages. Approved drug treatments have modest effects so there is a great need to develop long-term symptomatic improvement, with few side effects.
Montelukast buccal film is a thin edible film that is placed on the inside of the cheek, delivering medication as the film dissolves. It is currently marketed as Singulair®, an anti-inflammatory, for the treatment of asthma but research has suggested that Montelukast may play some role in lowering the chance of developing dementia later in life and might be able to improve learning, memory and overall cognitive functions. This study aims to formally test Montekulast as a potential treatment for Alzheimer’s disease.
Eligibility Criteria:- Aged 50 years or older
- Has a diagnosis of mild to moderate Alzheimer’s disease
- Have a study partner accompany them throughout the study
- Note: The eligibility criteria list is not exhaustive. Please contact the study team to find out the full eligibility criteria.
Recruitment Close Date:
December 31, 2022
Principal Investigator:Dr. Andrew Frank
Contact: Clinical Trials Research Unit: 613-562-6328 or
ctu@bruyere.orgREB#:M16-19-015. This study has been approved by the Bruyère Research Ethics Board.